Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan

Pharmacotherapy

Volumn 18, Issue 1, 1998, Pages 42-50

  Tenero, David ^a,b   Martin, David ^c   Chapelsky, Martha ^a,b   Ilson, Bernard ^c   Boike, Steven ^c   Patterson, Scott ^a   Keogh, John ^a,b   Rodriguez, Sheila ^d   Jorkasky, Diane ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b The Frythe ^*  (United Kingdom)

^c PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EPROSARTAN; HEMOGLOBIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; LIVER DISEASE; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PLASMA PROTEIN BINDING; TABLET;

ACRYLATES; ADULT; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; HUMANS; IMIDAZOLES; LIVER DISEASES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; THIOPHENES;

EID: 0031964678     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Sealy JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Laragh JH, Brunner HM, eds. Hypertension: pathophysiology, diagnosis and management. New York: Raven Press, 1990:1287-317.
2. Brogden RN, Todd PA, Sorkin EM. Captopril: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988;36:540-600.
3. Ilson B, Boike S, Audet P, et al. Renal hemodynamic effects of SK&F 108566, a nonpeptide selective angiotensin (AII) antagonist. Clin Pharmacol Ther 1994;55:206.
4. Cox P, Bush B, Gorycki P, et al. The metabolic fate of eprosartan in healthy volunteers. Exp Toxicol Pathol 1996;48:5.
5. Peck C, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Pharm Sci 1992;81:605-10.
6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
7. Lundberg DE, Person CR, Knox S, et al. Determination of SK&F 108566 in human plasma by solid-phase extraction cleanup and reversed-phased high-performance liquid chromatography. J Chromatogr In press.
8. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level time curve. J Pharmacokinet Biopharm 1978;6:539-47.
9. Child CG, Turcotte J. Surgery and portal hypertension. In: Child CG, ed. The liver and portal hypertension. Philadelphia: WB Saunders, 1964:50.
10. Saudek F, Moravek J, Modr A. Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujovirdin test. Int J Clinical Pharm Ther Toxicol 1989;27:82-7.